enGene Therapeutics (ENGN) Net Shares Issued and Repurchased (2023 - 2026)

enGene Therapeutics (ENGN) has 4 years of Net Shares Issued and Repurchased data on file, last reported at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Shares Issued and Repurchased rose 1.73% year-over-year to $3.2 million; the trailing twelve-month figure through Jan 2026 stood at $3.2 million (up 1.73% YoY), and the FY2025 full-year result was $4.9 million, up 37.19% from the prior year.
• Net Shares Issued and Repurchased was $3.2 million for Q1 2026 at enGene Therapeutics, down from $4.9 million in the prior quarter.
• In the past five years, Net Shares Issued and Repurchased ranged from a high of $4.9 million in Q4 2025 to a low of $144650.0 in Q2 2025.
• A 4-year average of $2.1 million and a median of $1.3 million in 2023 frame the typical range for Net Shares Issued and Repurchased.
• The largest YoY upside for Net Shares Issued and Repurchased was 428.51% in 2025 against a maximum downside of 56.27% in 2025.
• enGene Therapeutics' Net Shares Issued and Repurchased stood at $1.3 million in 2023, then soared by 174.54% to $3.6 million in 2024, then surged by 37.19% to $4.9 million in 2025, then slumped by 35.83% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Net Shares Issued and Repurchased figures were $3.2 million in Q1 2026, $4.9 million in Q4 2025, and $546650.0 in Q3 2025.